Tina St Biography and Net Worth

Insider of Immunocore

Tina joined Immunocore in January 2022 to lead the human resources function. Prior to Immunocore, Tina was Chief Human Resources Officer at GW Pharmaceuticals and led the company’s transition following its acquisition by Jazz Pharmaceuticals. Tina gained significant experience in HR working across several areas at GSK, including in emerging markets, Europe and in global therapy areas, as well as during her time as head of human resources for ViiV Healthcare. Tina began her pharmaceutical career in 2005 following an earlier career in finance at Marks and Spencer. She graduated with a chemistry degree from the University of St. Andrews.

What is Tina Amber St's net worth?: The estimated net worth of Tina Amber St is at least $37.31 thousand as of February 18th, 2026. St owns 1,119 shares of Immunocore stock worth more than $37,307 as of March 11th. This net worth evaluation does not reflect any other assets that St may own. Additionally, St receives an annual salary of $509,120.00 as Insider at Immunocore. Learn More about Tina Amber St's net worth.
How old is Tina Amber St?: St is currently 56 years old. There are 5 older executives and no younger executives at Immunocore. The oldest executive at Immunocore is Dr. Bahija Jallal Ph.D., CEO & Executive Director, who is 63 years old. Learn More on Tina Amber St's age.
What is Tina Amber St's salary?: As the Insider of Immunocore Holdings PLC Sponsored ADR, St earns $509,120.00 per year. There are 3 executives that earn more than St. The highest earning executive at Immunocore is Dr. Bahija Jallal Ph.D., CEO & Executive Director, who commands a salary of $1,380,000.00 per year. Learn More on Tina Amber St's salary.
How do I contact Tina Amber St?: The corporate mailing address for St and other Immunocore executives is 92 PARK DRIVE MILTON PARK ABINGDON, OXFORDSHIRE X0, OX14 4RY. Immunocore can also be reached via phone at 44-12-3543-8600 and via email at [email protected]. Learn More on Tina Amber St's contact information.
Has Tina Amber St been buying or selling shares of Immunocore?: In the last ninety days, Tina Amber St has sold $32,350.00 in shares of Immunocore stock. Most recently, Leger Tina Amber St sold 1,000 shares of the business's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a transaction totalling $32,350.00. Following the completion of the sale, the insider now directly owns 1,119 shares of the company's stock, valued at $36,199.65. Learn More on Tina Amber St's trading history.
Who are Immunocore's active insiders?: Immunocore's insider roster includes David Berman (Insider), John Goll (CAO), Bahija Jallal (CEO), and Tina St (Insider). Learn More on Immunocore's active insiders.
Are insiders buying or selling shares of Immunocore?: During the last twelve months, Immunocore insiders bought shares 1 times. They purchased a total of 807,338 shares worth more than $23,994,085.36. During the last twelve months, insiders at the sold shares 6 times. They sold a total of 41,869 shares worth more than $1,429,800.39. The most recent insider tranaction occured on February, 18th when CEO Bahija Jallal sold 11,474 shares worth more than $371,183.90. Insiders at Immunocore own 10.4% of the company. Learn More about insider trades at Immunocore.
Information on this page was last updated on 2/18/2026.

Tina Amber St Insider Trading History at Immunocore

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/18/2026	Sell	1,000	$32.35	$32,350.00	1,119
1/3/2024	Sell	4,375	$69.89	$305,768.75

Tina Amber St Buying and Selling Activity at Immunocore

Immunocore Company Overview

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Today's Range

Now: $33.34

$32.44

$33.85

50 Day Range

MA: $33.06

$30.92

$35.29

2 Week Range

Now: $33.34

$23.15

$40.71

Volume

158,646 shs

Average Volume

369,365 shs

Market Capitalization

$1.68 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78

Tina St Biography and Net Worth

What is Tina Amber St's net worth?

How old is Tina Amber St?

What is Tina Amber St's salary?

How do I contact Tina Amber St?

Has Tina Amber St been buying or selling shares of Immunocore?

Who are Immunocore's active insiders?

Are insiders buying or selling shares of Immunocore?